Vaxart (NASDAQ:VXRT) Shares Pass Below 200-Day Moving Average – Time to Sell?

Vaxart, Inc. (NASDAQ:VXRT)’s stock price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $0.74 and traded as low as $0.46. Vaxart shares last traded at $0.47, with a volume of 2,133,998 shares trading hands.

Vaxart Stock Performance

The stock has a market cap of $107.42 million, a PE ratio of -1.15 and a beta of 0.82. The company’s 50 day simple moving average is $0.71 and its 200 day simple moving average is $0.74.

Institutional Investors Weigh In On Vaxart

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Squarepoint Ops LLC increased its stake in Vaxart by 95.0% in the 4th quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company’s stock valued at $342,000 after buying an additional 251,789 shares during the last quarter. Graham Capital Management L.P. increased its stake in shares of Vaxart by 155.8% during the 4th quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 32,482 shares during the last quarter. Bank of America Corp DE increased its stake in shares of Vaxart by 10.8% during the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company’s stock worth $122,000 after purchasing an additional 17,942 shares during the last quarter. Silverarc Capital Management LLC increased its stake in shares of Vaxart by 7.8% during the 4th quarter. Silverarc Capital Management LLC now owns 1,077,782 shares of the biotechnology company’s stock worth $714,000 after purchasing an additional 77,782 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in shares of Vaxart during the 4th quarter worth approximately $129,000. Hedge funds and other institutional investors own 18.05% of the company’s stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company’s product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.